Agentix Corp. (AGTX): Total Liabilities
$3.60M
As of 2026-03-31
$3.71M
As of 2026-06-30
+12.7%
3-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | $3.60M | +12.2% | 2026-07-01, Balance as of period end |
| 2025-03-31 | $3.20M | +20.2% | 2026-07-01, Balance as of period end |
| 2024-03-31 | $2.67M | +6.2% | 2025-07-16, Balance as of period end |
| 2023-03-31 | $2.51M | +129.7% | 2024-08-30, Balance as of period end |
| 2022-03-31 | $1.09M | n/a | 2023-07-14, Balance as of period end |
| 2021-08-31 | $606.9K | +776.0% | 2021-10-07, Balance as of period end |
| 2020-08-31 | $69.3K | -45.0% | 2021-10-07, Balance as of period end |
| 2019-08-31 | $125.9K | +127.2% | 2019-12-05, Balance as of period end |
| 2018-08-31 | $55.4K | -23.2% | 2019-12-05, Balance as of period end |
| 2017-08-31 | $72.2K | n/m | 2018-11-13, Balance as of period end |
| 2016-08-31 | $3.7K | n/a | 2017-12-18, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Agentix Corp. (AGTX) | 2026-03-31 | $3.60M | +12.2% |
| Mosaic ImmunoEngineering Inc. (CPMV) | 2025-12-31 | $7.50M | +8.2% |
| Liminatus Pharma, Inc. (LIMN) | 2025-12-31 | $10.33M | -58.3% |
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $2.11M | -51.4% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $11.01M | +14.7% |
| Abpro Holdings, Inc. (ABPO) | 2024-12-31 | $19.61M | +21.1% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $13.54M | +351.9% |
Compare AGTX, CPMV, LIMN, APTN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗